Abstract 6068
Background
Photosensitizers (PS) are commonly used in photodynamic therapy to treat skin cancer. PS molecules bind to cell membrane and damage it by singlet oxygen (SO) generated under illumination. In our laboratory, we study in vitro the processes involved in photodynamic therapy on a model bilayer lipid membranes (BLM) by measuring the boundary potential applying the Intramembrane Field Compensation Method (Sokolov and Kuz’min, Biofizika, 25:170, 1980).
Methods
This method allowed to monitor the binding of PS on BLM and damage of target molecules (TM) of SO - di-4-ANEPPS under excitation of PS by light. In present investigation, we studied the adsorption and photodynamic efficiency of new positively charged porphyrins, namely b-imidazolyl substituted porphyrin and it’s Zn(II) and In(III) complexes; and two phosphorus (V) complexes of meso-(p-pyridyl)-triphenylporphyrin bearing hydroxyl and ethoxyl axial ligands. We observed a linear dependence of the boundary potential change on the logarithm of concentrations of each PS.
Results
The photodynamic efficiency of these porphyrins was assessed by determining the rate of oxidation (R) of TM adsorbed either on the same or opposite surface of the BLM where molecules PS were present. The values R for both positions of TM were close indicating that BLM is highly permeable to singlet oxygen. The values R were proportional to surface density of the porphyrin molecules in the membrane.
Conclusions
This investigation indicate that the main factor influencing the photodynamic efficiency of the porphyrins is their adsorption on the BLM. The work was supported by the Russian Foundation for Basic Research (project 19-04-00694) and the Ministry of Education and Science of the Russian Federation in the framework of Increase Competitiveness Program of NUST «MISiS» (№ К4-2017-053).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Science and Technology.
Funding
NUST-MISiS, Russian Science Foundation, Russian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1851 - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients
Presenter: Nobuaki Mamesaya
Session: Poster Display session 1
Resources:
Abstract
851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)
Presenter: Cristina Lopez Escola
Session: Poster Display session 1
Resources:
Abstract
3639 - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 1
Resources:
Abstract
2950 - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer
Presenter: Haixi Yan
Session: Poster Display session 1
Resources:
Abstract
3659 - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.
Presenter: Joori Kim
Session: Poster Display session 1
Resources:
Abstract
4882 - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment
Presenter: Florian Guisier
Session: Poster Display session 1
Resources:
Abstract
1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study
Presenter: Hayato Kawachi
Session: Poster Display session 1
Resources:
Abstract
3051 - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab
Presenter: Yuki Sato
Session: Poster Display session 1
Resources:
Abstract
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract